David Selewski
Concepts (315)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Acute Kidney Injury | 77 | 2025 | 392 | 15.710 |
Why?
| | Water-Electrolyte Imbalance | 24 | 2024 | 38 | 8.260 |
Why?
| | Nephrotic Syndrome | 15 | 2024 | 34 | 4.080 |
Why?
| | Extracorporeal Membrane Oxygenation | 17 | 2024 | 310 | 3.830 |
Why?
| | Renal Replacement Therapy | 17 | 2025 | 50 | 2.570 |
Why?
| | Infant, Newborn | 63 | 2025 | 2891 | 2.540 |
Why?
| | Quality of Life | 11 | 2019 | 882 | 2.360 |
Why?
| | Critical Illness | 20 | 2025 | 312 | 2.250 |
Why?
| | Water-Electrolyte Balance | 11 | 2023 | 30 | 2.040 |
Why?
| | Renal Insufficiency, Chronic | 11 | 2025 | 203 | 1.980 |
Why?
| | Child | 69 | 2025 | 7229 | 1.960 |
Why?
| | Nephrology | 12 | 2023 | 26 | 1.750 |
Why?
| | Intensive Care Units, Pediatric | 12 | 2023 | 158 | 1.650 |
Why?
| | Humans | 132 | 2025 | 52593 | 1.500 |
Why?
| | Heart Failure | 6 | 2024 | 587 | 1.490 |
Why?
| | Retrospective Studies | 57 | 2025 | 6671 | 1.490 |
Why?
| | Kidney Diseases | 9 | 2022 | 231 | 1.440 |
Why?
| | Hospital Mortality | 11 | 2024 | 459 | 1.430 |
Why?
| | Hypothermia, Induced | 6 | 2021 | 46 | 1.390 |
Why?
| | Risk Factors | 41 | 2025 | 3952 | 1.290 |
Why?
| | Creatinine | 10 | 2023 | 159 | 1.090 |
Why?
| | Infant | 34 | 2025 | 3720 | 1.090 |
Why?
| | Adolescent | 40 | 2025 | 6737 | 1.080 |
Why?
| | Child, Preschool | 31 | 2025 | 4062 | 1.050 |
Why?
| | Kidney | 16 | 2025 | 723 | 1.050 |
Why?
| | Health Status | 3 | 2017 | 300 | 1.030 |
Why?
| | Cardiac Surgical Procedures | 7 | 2023 | 328 | 1.020 |
Why?
| | Asphyxia Neonatorum | 3 | 2021 | 9 | 1.010 |
Why?
| | Erythropoietin | 2 | 2023 | 52 | 1.010 |
Why?
| | Male | 66 | 2025 | 26863 | 1.000 |
Why?
| | Bronchopulmonary Dysplasia | 2 | 2023 | 63 | 0.970 |
Why?
| | Intensive Care Units, Neonatal | 9 | 2025 | 145 | 0.950 |
Why?
| | Female | 62 | 2025 | 28262 | 0.900 |
Why?
| | Renal Dialysis | 12 | 2024 | 191 | 0.890 |
Why?
| | Infant, Premature | 8 | 2025 | 327 | 0.860 |
Why?
| | Glomerulosclerosis, Focal Segmental | 5 | 2023 | 20 | 0.860 |
Why?
| | Acid-Base Imbalance | 1 | 2023 | 2 | 0.820 |
Why?
| | Respiration, Artificial | 7 | 2022 | 298 | 0.820 |
Why?
| | Self Report | 7 | 2019 | 215 | 0.820 |
Why?
| | Cardiopulmonary Resuscitation | 3 | 2022 | 123 | 0.800 |
Why?
| | Infant, Newborn, Diseases | 1 | 2023 | 57 | 0.790 |
Why?
| | Cohort Studies | 11 | 2024 | 1553 | 0.720 |
Why?
| | Hypoxia-Ischemia, Brain | 4 | 2021 | 64 | 0.720 |
Why?
| | Length of Stay | 13 | 2024 | 674 | 0.710 |
Why?
| | Critical Care | 5 | 2022 | 222 | 0.710 |
Why?
| | Kidney Transplantation | 8 | 2022 | 200 | 0.710 |
Why?
| | Severity of Illness Index | 9 | 2024 | 1037 | 0.710 |
Why?
| | Infant Nutritional Physiological Phenomena | 1 | 2021 | 55 | 0.690 |
Why?
| | Nutritional Requirements | 1 | 2021 | 68 | 0.690 |
Why?
| | Hospitalization | 6 | 2024 | 749 | 0.670 |
Why?
| | Time Factors | 11 | 2020 | 3000 | 0.660 |
Why?
| | Consensus | 7 | 2025 | 190 | 0.650 |
Why?
| | Quality Improvement | 2 | 2021 | 224 | 0.630 |
Why?
| | Prognosis | 12 | 2025 | 2118 | 0.590 |
Why?
| | Birth Weight | 5 | 2023 | 129 | 0.590 |
Why?
| | Ductus Arteriosus, Patent | 3 | 2023 | 40 | 0.560 |
Why?
| | Kidney Glomerulus | 2 | 2022 | 43 | 0.550 |
Why?
| | Prospective Studies | 11 | 2024 | 2457 | 0.550 |
Why?
| | Acute Disease | 6 | 2023 | 387 | 0.540 |
Why?
| | Infant, Very Low Birth Weight | 4 | 2025 | 55 | 0.540 |
Why?
| | Young Adult | 15 | 2025 | 4337 | 0.540 |
Why?
| | Treatment Outcome | 21 | 2024 | 5486 | 0.540 |
Why?
| | Postoperative Complications | 7 | 2024 | 1081 | 0.510 |
Why?
| | Vitamin D Deficiency | 1 | 2015 | 46 | 0.470 |
Why?
| | Registries | 3 | 2025 | 629 | 0.470 |
Why?
| | Vitamin D | 1 | 2015 | 90 | 0.470 |
Why?
| | Research Subjects | 1 | 2015 | 53 | 0.460 |
Why?
| | Heart Defects, Congenital | 4 | 2025 | 622 | 0.460 |
Why?
| | Longitudinal Studies | 6 | 2024 | 747 | 0.450 |
Why?
| | Gestational Age | 6 | 2024 | 418 | 0.450 |
Why?
| | Hypertension | 4 | 2024 | 570 | 0.450 |
Why?
| | Infant, Premature, Diseases | 3 | 2019 | 97 | 0.430 |
Why?
| | Patient Selection | 1 | 2015 | 266 | 0.430 |
Why?
| | Databases, Factual | 4 | 2024 | 715 | 0.420 |
Why?
| | Biomedical Research | 2 | 2024 | 258 | 0.420 |
Why?
| | Hydrocortisone | 2 | 2024 | 113 | 0.420 |
Why?
| | Kidney Failure, Chronic | 5 | 2019 | 216 | 0.420 |
Why?
| | Multivariate Analysis | 6 | 2025 | 602 | 0.400 |
Why?
| | Persistent Fetal Circulation Syndrome | 2 | 2023 | 12 | 0.400 |
Why?
| | Health Services | 1 | 2013 | 66 | 0.400 |
Why?
| | Acidosis, Lactic | 2 | 2023 | 7 | 0.390 |
Why?
| | Incidence | 9 | 2024 | 1077 | 0.390 |
Why?
| | Patient Acceptance of Health Care | 3 | 2022 | 358 | 0.380 |
Why?
| | Obesity, Morbid | 1 | 2013 | 89 | 0.370 |
Why?
| | Multiple Organ Failure | 2 | 2022 | 49 | 0.370 |
Why?
| | Blood Component Removal | 2 | 2022 | 17 | 0.370 |
Why?
| | Fatigue | 4 | 2017 | 129 | 0.370 |
Why?
| | United States | 14 | 2024 | 5227 | 0.360 |
Why?
| | Risk Assessment | 5 | 2024 | 1350 | 0.360 |
Why?
| | Metformin | 2 | 2023 | 81 | 0.360 |
Why?
| | Nephrosis, Lipoid | 2 | 2023 | 7 | 0.350 |
Why?
| | Linear Models | 5 | 2025 | 292 | 0.340 |
Why?
| | Drug Overdose | 2 | 2023 | 165 | 0.330 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2010 | 47 | 0.330 |
Why?
| | Meningitis | 1 | 2010 | 25 | 0.330 |
Why?
| | Delphi Technique | 3 | 2025 | 63 | 0.330 |
Why?
| | Norwood Procedures | 2 | 2024 | 62 | 0.330 |
Why?
| | Lymphoma, B-Cell | 1 | 2010 | 62 | 0.320 |
Why?
| | Out-of-Hospital Cardiac Arrest | 2 | 2021 | 28 | 0.320 |
Why?
| | Pain | 3 | 2017 | 362 | 0.310 |
Why?
| | Body Weight | 1 | 2011 | 523 | 0.300 |
Why?
| | Renal Insufficiency | 2 | 2022 | 115 | 0.290 |
Why?
| | Respiratory Insufficiency | 2 | 2020 | 117 | 0.290 |
Why?
| | Hospitals, Pediatric | 3 | 2021 | 243 | 0.280 |
Why?
| | Adult | 14 | 2025 | 14170 | 0.270 |
Why?
| | Odds Ratio | 4 | 2021 | 568 | 0.270 |
Why?
| | Depression | 4 | 2017 | 604 | 0.270 |
Why?
| | Glomerulonephritis | 2 | 2019 | 17 | 0.260 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 2 | 2019 | 124 | 0.260 |
Why?
| | Fluid Therapy | 2 | 2020 | 80 | 0.260 |
Why?
| | Brain Neoplasms | 1 | 2010 | 290 | 0.260 |
Why?
| | Proteinuria | 2 | 2017 | 41 | 0.260 |
Why?
| | Health Information Systems | 2 | 2024 | 18 | 0.250 |
Why?
| | Cross-Sectional Studies | 7 | 2020 | 1686 | 0.250 |
Why?
| | Logistic Models | 6 | 2021 | 934 | 0.250 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 2 | 2016 | 82 | 0.240 |
Why?
| | Organ Dysfunction Scores | 2 | 2022 | 20 | 0.240 |
Why?
| | Patient Discharge | 2 | 2020 | 326 | 0.230 |
Why?
| | Hospital Costs | 1 | 2024 | 73 | 0.220 |
Why?
| | Anger | 2 | 2015 | 17 | 0.220 |
Why?
| | Vasopressins | 1 | 2024 | 39 | 0.220 |
Why?
| | Michigan | 4 | 2021 | 26 | 0.220 |
Why?
| | North America | 3 | 2018 | 77 | 0.210 |
Why?
| | Vasoconstrictor Agents | 1 | 2024 | 81 | 0.210 |
Why?
| | Dyslipidemias | 1 | 2024 | 43 | 0.210 |
Why?
| | Midwestern United States | 4 | 2015 | 26 | 0.210 |
Why?
| | Glomerulonephritis, IGA | 1 | 2023 | 5 | 0.210 |
Why?
| | Annual Reports as Topic | 3 | 2018 | 6 | 0.210 |
Why?
| | Ductus Arteriosus | 1 | 2023 | 11 | 0.210 |
Why?
| | Fontan Procedure | 1 | 2024 | 68 | 0.200 |
Why?
| | Thrombocytopenia | 1 | 2024 | 92 | 0.200 |
Why?
| | Heart Diseases | 1 | 2025 | 226 | 0.190 |
Why?
| | Lupus Nephritis | 1 | 2022 | 18 | 0.190 |
Why?
| | Survival Rate | 3 | 2020 | 952 | 0.190 |
Why?
| | Child Development | 1 | 2024 | 201 | 0.190 |
Why?
| | Hypernatremia | 1 | 2021 | 3 | 0.190 |
Why?
| | Hyponatremia | 1 | 2021 | 13 | 0.190 |
Why?
| | Cardiovascular Diseases | 2 | 2019 | 495 | 0.190 |
Why?
| | Caffeine | 2 | 2021 | 63 | 0.190 |
Why?
| | Antineoplastic Agents | 1 | 2010 | 1221 | 0.180 |
Why?
| | Multicenter Studies as Topic | 4 | 2024 | 112 | 0.180 |
Why?
| | Parenteral Nutrition | 1 | 2021 | 28 | 0.180 |
Why?
| | Blood Pressure | 1 | 2024 | 537 | 0.180 |
Why?
| | Aminoglycosides | 2 | 2023 | 20 | 0.180 |
Why?
| | Immunosuppressive Agents | 2 | 2015 | 250 | 0.180 |
Why?
| | Hypothermia | 1 | 2021 | 38 | 0.180 |
Why?
| | Survival Analysis | 2 | 2020 | 673 | 0.170 |
Why?
| | Goals | 1 | 2021 | 44 | 0.170 |
Why?
| | Nutritional Status | 1 | 2021 | 138 | 0.170 |
Why?
| | Enteral Nutrition | 1 | 2021 | 155 | 0.170 |
Why?
| | Graft Rejection | 2 | 2018 | 179 | 0.160 |
Why?
| | Fluid Shifts | 1 | 2019 | 3 | 0.160 |
Why?
| | Tertiary Care Centers | 1 | 2020 | 83 | 0.160 |
Why?
| | Canada | 1 | 2019 | 107 | 0.160 |
Why?
| | Information Systems | 2 | 2016 | 29 | 0.160 |
Why?
| | Anemia, Sickle Cell | 2 | 2017 | 103 | 0.150 |
Why?
| | Age Factors | 2 | 2020 | 1132 | 0.150 |
Why?
| | Healthcare Disparities | 1 | 2022 | 300 | 0.150 |
Why?
| | Term Birth | 1 | 2018 | 17 | 0.150 |
Why?
| | Sample Size | 2 | 2015 | 46 | 0.150 |
Why?
| | Prevalence | 5 | 2024 | 1017 | 0.150 |
Why?
| | India | 1 | 2018 | 64 | 0.150 |
Why?
| | Renal Agents | 1 | 2018 | 2 | 0.150 |
Why?
| | Streptococcus pneumoniae | 1 | 2018 | 27 | 0.150 |
Why?
| | Cerebral Hemorrhage | 1 | 2019 | 100 | 0.150 |
Why?
| | Citrates | 1 | 2018 | 10 | 0.150 |
Why?
| | Edema | 1 | 2019 | 66 | 0.150 |
Why?
| | Pneumococcal Infections | 1 | 2018 | 15 | 0.150 |
Why?
| | ROC Curve | 3 | 2017 | 254 | 0.140 |
Why?
| | Endpoint Determination | 1 | 2017 | 26 | 0.140 |
Why?
| | Cardiopulmonary Bypass | 3 | 2023 | 96 | 0.140 |
Why?
| | Glomerular Filtration Rate | 4 | 2022 | 130 | 0.140 |
Why?
| | Pediatrics | 3 | 2015 | 295 | 0.140 |
Why?
| | Anti-Bacterial Agents | 2 | 2023 | 803 | 0.140 |
Why?
| | Blood Glucose | 2 | 2017 | 473 | 0.140 |
Why?
| | Venous Thromboembolism | 1 | 2018 | 76 | 0.140 |
Why?
| | Enterocolitis, Necrotizing | 1 | 2017 | 40 | 0.140 |
Why?
| | Weight Gain | 1 | 2018 | 241 | 0.130 |
Why?
| | Hyperglycemia | 1 | 2017 | 89 | 0.130 |
Why?
| | Clinical Trials as Topic | 2 | 2016 | 472 | 0.130 |
Why?
| | Hypoglycemia | 1 | 2017 | 60 | 0.130 |
Why?
| | Interpersonal Relations | 1 | 2017 | 107 | 0.130 |
Why?
| | Premature Birth | 1 | 2018 | 150 | 0.130 |
Why?
| | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 1 | 2016 | 5 | 0.130 |
Why?
| | Acyclovir | 1 | 2016 | 9 | 0.130 |
Why?
| | Pseudohypoaldosteronism | 1 | 2016 | 8 | 0.130 |
Why?
| | Amphotericin B | 1 | 2016 | 104 | 0.120 |
Why?
| | Terminology as Topic | 1 | 2016 | 71 | 0.120 |
Why?
| | Fibroblast Growth Factors | 1 | 2016 | 47 | 0.120 |
Why?
| | Steroids | 1 | 2015 | 60 | 0.120 |
Why?
| | Vancomycin | 1 | 2016 | 86 | 0.120 |
Why?
| | Judgment | 1 | 2015 | 12 | 0.120 |
Why?
| | Awards and Prizes | 1 | 2015 | 19 | 0.120 |
Why?
| | Community-Institutional Relations | 1 | 2015 | 47 | 0.120 |
Why?
| | Time | 1 | 2015 | 29 | 0.120 |
Why?
| | Recurrence | 3 | 2023 | 683 | 0.120 |
Why?
| | Spectroscopy, Near-Infrared | 1 | 2015 | 52 | 0.120 |
Why?
| | Renin-Angiotensin System | 1 | 2015 | 58 | 0.120 |
Why?
| | Hypoplastic Left Heart Syndrome | 1 | 2016 | 99 | 0.120 |
Why?
| | Anxiety | 1 | 2017 | 301 | 0.110 |
Why?
| | Area Under Curve | 2 | 2014 | 183 | 0.110 |
Why?
| | Parathyroid Hormone | 1 | 2015 | 151 | 0.110 |
Why?
| | Maternal Exposure | 1 | 2015 | 102 | 0.110 |
Why?
| | Fetus | 1 | 2015 | 195 | 0.110 |
Why?
| | Statistics, Nonparametric | 2 | 2012 | 196 | 0.110 |
Why?
| | Diagnosis, Differential | 2 | 2016 | 1048 | 0.110 |
Why?
| | Palliative Care | 1 | 2016 | 216 | 0.110 |
Why?
| | Regional Blood Flow | 1 | 2014 | 107 | 0.110 |
Why?
| | Educational Measurement | 1 | 2015 | 198 | 0.100 |
Why?
| | Follow-Up Studies | 4 | 2025 | 2291 | 0.100 |
Why?
| | Electroencephalography | 1 | 2015 | 313 | 0.100 |
Why?
| | Hospital Charges | 1 | 2013 | 47 | 0.100 |
Why?
| | Biopsy | 3 | 2023 | 607 | 0.100 |
Why?
| | Intensive Care, Neonatal | 1 | 2012 | 24 | 0.100 |
Why?
| | Reproducibility of Results | 2 | 2013 | 1217 | 0.100 |
Why?
| | Ibuprofen | 2 | 2023 | 24 | 0.100 |
Why?
| | Delivery of Health Care | 1 | 2015 | 324 | 0.100 |
Why?
| | Chronic Disease | 1 | 2015 | 588 | 0.100 |
Why?
| | Neonatology | 2 | 2024 | 15 | 0.100 |
Why?
| | Attitude of Health Personnel | 1 | 2015 | 361 | 0.090 |
Why?
| | Activities of Daily Living | 1 | 2013 | 183 | 0.090 |
Why?
| | Dietary Supplements | 1 | 2015 | 465 | 0.090 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2015 | 510 | 0.090 |
Why?
| | Stem Cell Transplantation | 1 | 2012 | 187 | 0.090 |
Why?
| | Combined Modality Therapy | 1 | 2012 | 639 | 0.080 |
Why?
| | Pulse Therapy, Drug | 1 | 2010 | 4 | 0.080 |
Why?
| | Cranial Nerve Diseases | 1 | 2010 | 16 | 0.080 |
Why?
| | Intensive Care Units | 2 | 2024 | 236 | 0.080 |
Why?
| | Neoplasms | 2 | 2017 | 1308 | 0.080 |
Why?
| | Drug Resistance | 2 | 2021 | 68 | 0.080 |
Why?
| | Postoperative Period | 2 | 2023 | 172 | 0.080 |
Why?
| | Cyclophosphamide | 1 | 2010 | 172 | 0.080 |
Why?
| | Glucocorticoids | 2 | 2024 | 238 | 0.080 |
Why?
| | Internationality | 2 | 2019 | 46 | 0.080 |
Why?
| | Research Design | 2 | 2024 | 358 | 0.070 |
Why?
| | Disease Progression | 2 | 2023 | 873 | 0.070 |
Why?
| | Brain | 1 | 2015 | 1325 | 0.070 |
Why?
| | Magnetic Resonance Imaging | 1 | 2013 | 1545 | 0.060 |
Why?
| | Aged | 3 | 2019 | 10191 | 0.060 |
Why?
| | Information Dissemination | 2 | 2016 | 86 | 0.060 |
Why?
| | Aftercare | 1 | 2025 | 72 | 0.060 |
Why?
| | Infant Mortality | 2 | 2017 | 64 | 0.060 |
Why?
| | Adrenal Insufficiency | 1 | 2024 | 19 | 0.050 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2010 | 1031 | 0.050 |
Why?
| | Body Height | 1 | 2024 | 67 | 0.050 |
Why?
| | Growth Disorders | 1 | 2024 | 65 | 0.050 |
Why?
| | Immunoglobulin A | 1 | 2023 | 46 | 0.050 |
Why?
| | Indomethacin | 1 | 2023 | 36 | 0.050 |
Why?
| | Apolipoproteins | 1 | 2023 | 14 | 0.050 |
Why?
| | Lipids | 1 | 2024 | 160 | 0.050 |
Why?
| | Catheters, Indwelling | 1 | 2023 | 59 | 0.050 |
Why?
| | Child, Hospitalized | 1 | 2023 | 32 | 0.050 |
Why?
| | Age of Onset | 1 | 2023 | 110 | 0.050 |
Why?
| | Focus Groups | 1 | 2023 | 197 | 0.050 |
Why?
| | Educational Status | 1 | 2023 | 228 | 0.050 |
Why?
| | Societies, Medical | 1 | 2023 | 202 | 0.050 |
Why?
| | Genome-Wide Association Study | 1 | 2023 | 187 | 0.050 |
Why?
| | Social Class | 1 | 2022 | 94 | 0.050 |
Why?
| | Prostaglandins | 1 | 2021 | 21 | 0.050 |
Why?
| | Theophylline | 1 | 2021 | 18 | 0.050 |
Why?
| | Sclerosis | 1 | 2021 | 4 | 0.050 |
Why?
| | Genotype | 1 | 2023 | 571 | 0.050 |
Why?
| | Practice Guidelines as Topic | 1 | 2024 | 496 | 0.040 |
Why?
| | Remission Induction | 1 | 2021 | 219 | 0.040 |
Why?
| | Research | 1 | 2021 | 107 | 0.040 |
Why?
| | Chi-Square Distribution | 1 | 2021 | 295 | 0.040 |
Why?
| | Hypoglycemic Agents | 1 | 2023 | 217 | 0.040 |
Why?
| | Oxygen Consumption | 1 | 2021 | 200 | 0.040 |
Why?
| | Lipoproteins, LDL | 1 | 2022 | 170 | 0.040 |
Why?
| | Evidence-Based Medicine | 1 | 2022 | 269 | 0.040 |
Why?
| | Heart | 1 | 2022 | 361 | 0.040 |
Why?
| | Infant, Extremely Premature | 1 | 2019 | 32 | 0.040 |
Why?
| | Risk Adjustment | 1 | 2019 | 17 | 0.040 |
Why?
| | Mortality | 1 | 2019 | 105 | 0.040 |
Why?
| | Coma | 1 | 2018 | 17 | 0.040 |
Why?
| | Preoperative Period | 1 | 2018 | 47 | 0.040 |
Why?
| | Health Expenditures | 1 | 2019 | 74 | 0.040 |
Why?
| | Research Report | 1 | 2018 | 18 | 0.040 |
Why?
| | Middle Aged | 3 | 2019 | 13096 | 0.040 |
Why?
| | Monitoring, Physiologic | 1 | 2017 | 123 | 0.030 |
Why?
| | Proportional Hazards Models | 1 | 2017 | 444 | 0.030 |
Why?
| | Morbidity | 1 | 2017 | 143 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2017 | 485 | 0.030 |
Why?
| | Diastole | 1 | 2015 | 68 | 0.030 |
Why?
| | Systole | 1 | 2015 | 74 | 0.030 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2016 | 237 | 0.030 |
Why?
| | Pregnancy Trimester, Second | 1 | 2015 | 28 | 0.030 |
Why?
| | Medical Records | 1 | 2015 | 87 | 0.030 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2015 | 43 | 0.030 |
Why?
| | Pregnancy Trimester, Third | 1 | 2015 | 58 | 0.030 |
Why?
| | Cholesterol | 1 | 2015 | 157 | 0.030 |
Why?
| | Rheumatic Diseases | 1 | 2015 | 18 | 0.030 |
Why?
| | Regression Analysis | 1 | 2016 | 403 | 0.030 |
Why?
| | Animals | 2 | 2023 | 13507 | 0.030 |
Why?
| | Emergency Service, Hospital | 1 | 2019 | 524 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2017 | 600 | 0.030 |
Why?
| | Ventricular Function, Left | 1 | 2015 | 177 | 0.030 |
Why?
| | Blood Pressure Determination | 1 | 2014 | 43 | 0.030 |
Why?
| | Weight Loss | 1 | 2016 | 250 | 0.030 |
Why?
| | Sensitivity and Specificity | 1 | 2016 | 883 | 0.030 |
Why?
| | Software | 1 | 2015 | 280 | 0.030 |
Why?
| | Mice | 1 | 2023 | 5958 | 0.020 |
Why?
| | Ultrafiltration | 1 | 2012 | 6 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2016 | 1202 | 0.020 |
Why?
| | Hemofiltration | 1 | 2012 | 8 | 0.020 |
Why?
| | Pilot Projects | 1 | 2015 | 721 | 0.020 |
Why?
| | International Cooperation | 1 | 2012 | 52 | 0.020 |
Why?
| | Body Mass Index | 1 | 2015 | 692 | 0.020 |
Why?
| | Parents | 1 | 2015 | 332 | 0.020 |
Why?
| | Hernia, Diaphragmatic | 1 | 2011 | 22 | 0.020 |
Why?
| | Equipment Design | 1 | 2012 | 288 | 0.020 |
Why?
| | Asthma | 1 | 2015 | 317 | 0.020 |
Why?
| | Pregnancy | 1 | 2015 | 2679 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2015 | 3420 | 0.020 |
Why?
| | Obesity | 1 | 2015 | 1165 | 0.020 |
Why?
|
|
Selewski's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|